Transportation Battery Market Forecast Report and Company Analysis 2025-2033 Featuring Panasonic, Exide Industries, VARTA, Hitachi, Robert Bosch, SAMSUNG, and LG Chem
The global transportation battery market is projected to surge from USD 97.07 billion in 2024 to USD 300.08 billion by 2033, driven by electric vehicle adoption, advancements in battery technology, and supportive government policies. Key players include Panasonic, Exide, VARTA, Hitachi, Bosch, SAMSUNG SDI, and LG Chem.
Transportation Battery Market
Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "Transportation Battery Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" report has been added to ResearchAndMarkets.com's offering.The Transportation Battery Market is expected to reach US$ 300.08 billion by 2033 from US$ 97.07 billion in 2024, with a CAGR of 13.36% from 2025 to 2033. Growing Electrification, Development of Charging Infrastructure, Growing Adoption of Electric Vehicles, Grid Integration, and Energy Storage are the Main Drivers of Market Growth.
The growing demand for electric vehicles (EVs) and environmentally friendly transportation options is propelling the worldwide transportation battery market's explosive expansion. Batteries are now the mainstay of the electric transportation revolution as governments and corporations throughout the world strive for more environmentally friendly substitutes for conventional gasoline and diesel-powered automobiles. These batteries provide a cleaner, more energy-efficient way to lessen carbon emissions and dependency on fossil fuels by powering electric cars, buses, trucks, and other modes of transportation. Electric vehicles are becoming more affordable and effective thanks to major improvements in energy density, charging speed, and longevity brought about by advancements in battery technology, especially lithium-ion batteries.The global transition to renewable energy sources and the increased focus on minimizing environmental effect across businesses provide additional support for the sector. In order to address the growing demand for electric automobiles and other electric transportation modes, investments in battery production, innovation, and recycling technologies are essential. Energy suppliers, electric vehicle manufacturers, and battery makers are major participants in the industry; they collaborate to cut costs, improve infrastructure, and increase battery performance. But there are still issues including a lack of raw materials, high production costs, and the requirement for a strong charging infrastructure. Despite these hurdles, the worldwide transportation battery market is likely to continue its rise, driven by advancements in technology and environmental policies.To cut greenhouse gas emissions and fight climate change, governments everywhere are enacting legislation and offering incentives to promote the use of electric vehicles. These policies include stringent emissions limitations, tax rebates, grants, and subsidies for EV purchasers. They also involve investments in charging infrastructure. The demand for EV batteries rises as a result of these initiatives, which lower the total cost of ownership for EVs and increase their appeal to both businesses and consumers.Furthermore, as environmental issues like air pollution and climate change become more widely recognized, there is an increasing demand for sustainable and eco-friendly transportation options. An increasingly viable solution to these environmental issues is the use of electric vehicles, which are cleaner and more energy-efficient than internal combustion engines. Automobile manufacturers are investing in research into electric cars and the batteries that power them as a result of this change in consumer preferences.Growth Drivers for the Transportation Battery Market
Increasing Adoption of Electric Vehicles (EVs)The primary factor propelling the expansion of the transportation battery market is the growing use of electric cars (EVs). Electric-powered transportation is becoming more and more popular among consumers and businesses as governments around the world impose more stringent emissions rules and set ambitious carbon reduction targets.
The purchase of EVs is also being encouraged by a number of incentives, including grants, tax reductions, and subsidies. Since they provide a cleaner and more environmentally friendly option to conventional internal combustion engine vehicles, the demand for electric vehicles - including passenger cars, buses, and commercial trucks - is growing quickly. The market for transportation batteries is expanding as a result of the direct need for more effective, larger-capacity batteries brought on by the rise in EV adoption.Government Regulations and IncentivesThe market for transportation batteries is expanding due in large part to government policies and incentives. Electric vehicles (EVs) are becoming more and more popular among manufacturers and consumers due to strict environmental regulations, such as fuel economy requirements, carbon reduction targets, and emissions limits.
To increase the accessibility of EVs, governments are increasingly enforcing laws requiring reduced car emissions and providing a range of incentives. These lower the total cost of electric vehicles by providing grants, tax incentives, and subsidies to EV producers and consumers. These policies promote investment in EV infrastructure, including charging stations, in addition to encouraging the use of EVs. Accelerating the shift to electric vehicles and growing the market for transportation batteries require the backing of governments everywhere.Technological Advancements in Battery TechnologyThe market for transportation batteries is expanding at a rapid pace due to developments in battery technology. Energy density, charging rates, and overall efficiency have all increased as a result of innovations, especially in solid-state and lithium-ion batteries. Electric vehicles (EVs) are becoming increasingly feasible for everyday usage as lithium-ion batteries get lighter, stronger, and last longer.
Even greater energy densities, quicker charging periods, and increased safety are promised by solid-state batteries, which are now under development. These developments solve major issues like range anxiety and lengthy charging times, making electric vehicles not only more practical but also more appealing to businesses and customers. The market for transportation batteries is anticipated to grow as EV adoption picks up speed as battery technology advances.Challenges in the Transportation Battery Market
Battery Recycling and DisposalEffective battery recycling and disposal solutions are becoming increasingly important as the number of electric vehicles (EVs) rises. Batteries for electric vehicles, especially lithium-ion batteries, contain elements like nickel, cobalt, and lithium that, if improperly recycled, can be hazardous to the environment.
If these batteries are disposed of improperly, there may be hazardous leaks, contaminated water and soil, and substantial resource waste. In order to recover valuable materials and lessen the environmental impact of spent batteries, efficient recycling procedures are required. But the infrastructure to manage the increasing amount of wasted batteries is still in its infancy, and the recycling solutions available today aren't always optimum. Reducing environmental damage and guaranteeing sustainable growth in the transportation battery business depend on resolving this issue.Battery Performance and LongevityIn the market for electric vehicles (EVs), battery longevity and performance continue to be major obstacles. Even though battery technology has improved, consumers are still concerned about problems like gradual battery depletion and short driving range. Battery capacity might degrade with time, resulting in a shorter range and a need for more frequent charging, which impacts the user experience as a whole. This deterioration, together with worries about replacement prices, may put off prospective EV purchasers.
Manufacturers are working to improve battery life, maximize energy efficiency, and create more durable solutions in order to address these problems. In the transportation battery market, resolving these performance issues is essential to promoting wider EV adoption and guaranteeing sustained customer happiness.
Key Players Analysis: Overview, Key Persons, Recent Development & Strategies, Product Portfolio, Financial Insights
Panasonic Corporation
Exide Industries
VARTA
Hitachi Group Ltd
Robert Bosch GmbH
SAMSUNG SDI Co. Ltd
LG Chem Ltd
Key Attributes:
Report Attribute
Details
No. of Pages
200
Forecast Period
2024 - 2033
Estimated Market Value (USD) in 2024
$97.07 Billion
Forecasted Market Value (USD) by 2033
$300.08 Billion
Compound Annual Growth Rate
13.3%
Regions Covered
Global
Key Topics Covered: 1. Introduction2. Research Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Global Transportation Battery Market6. Market Share6.1 Battery Type6.2 Types6.3 Drive Type6.4 Country7. Battery Type7.1 Lead-Acid7.2 Lithium-Ion7.3 Other Battery8. Types8.1 Vehicle Type8.2 Passenger Cars8.3 Commercial Vehicles9. Drive Type9.1 Internal Combustion Engine9.2 Electric Vehicles10. Country10.1 North America10.1.1 United States10.1.2 Canada10.2 Europe10.2.1 France10.2.2 Germany10.2.3 Italy10.2.4 Spain10.2.5 United Kingdom10.2.6 Belgium10.2.7 Netherlands10.2.8 Turkey10.3 Asia-Pacific10.3.1 China10.3.2 Japan10.3.3 India10.3.4 Australia10.3.5 South Korea10.3.6 Thailand10.3.7 Malaysia10.3.8 Indonesia10.3.9 New Zealand10.4 Latin America10.4.1 Brazil10.4.2 Mexico10.4.3 Argentina10.5 Middle East & Africa10.5.1 South Africa10.5.2 Saudi Arabia10.5.3 UAE11. Porter's Five Analysis11.1 Bargaining Power of Buyers11.2 Bargaining Power of Suppliers11.3 Degree of Rivalry11.4 Threat of New Entrants11.5 Threat of Substitutes12. SWOT Analysis12.1 Strength12.2 Weakness12.3 Opportunity12.4 Threat13. Key Players Analysis
For more information about this report visit https://www.researchandmarkets.com/r/mqdvxo
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
Transportation Battery Market
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
US-China trade, inflation, Apple's big event: Here's what the stock market is watching this week
There's a handful of potentially market-moving events on the calendar this week. US-China trade talks and May inflation data will be the highest-profile events for traders. Apple's WWDC will shed light on the company's supply chain and AI strategy. Investors will be monitoring a host of potentially market-moving events this week, with updates due on trade and inflation, while Apple kicks off a highly anticipated product event. Recession fears have edged down after the turmoil that racked markets earlier in the spring, but the market is still struggling with uncertainty regarding President Donald Trump's trade policies and their implications for the economy. While last week's jobs report showed a solid labor market, investors are monitoring how the inflation side of the Federal Reserve's dual mandate fares this week, and how it will influence the rate-cut outlook for the year. Meanwhile, Apple's Worldwide Developers Conference will provide insight into not only new software updates but also the future of the AI race among mega-cap tech companies. Here's what investors are watching this week. After last week's phone call between Trump and Chinese president Xi Jinping, China and US trade officials are meeting in London on Monday for two days of trade negotiations. Last month's trade talks were key to calming recession fears and helped propel the S&P 500 to its highest levels since February, but concerns still remain. The biggest negotiation topic will be over China's exports of rare earth metals, which are critical components in manufacturing semiconductors, smartphones, and other technologies. Continued improvements in trade relations between the two countries will be critical to reducing volatility in the market and could shed clarity on the direction of tariff rates. The consumer price index for May will be released on Wednesday. Last month's reading of 2.3% was fairly benign, but investors will continue to watch for signs of Trump's tariffs showing up in the hard data. Importantly, the reading will be key in determining the Fed's next move. The median forecast is for annual consumer inflation to have risen 2.5% last month. Meanwhile, expectations for the June 17 Fed meeting are for officials to keep interest rates unchanged. "The big surprise could be how little Trump's tariffs are boosting inflation despite upward pressures on prices-paid and prices-received indexes in the Fed's regional business surveys," wrote on Sunday. Yet, some strategists have predicted that inflation will pick up in the back half of this year, spurring stagflation concerns. Meanwhile, consumer sentiment will get a fresh reading on Friday. Sentiment has been low as Americans feel pessimistic about tariffs, though hard data that the Fed looks at has held up. All eyes will be on Apple this week as it kicks off its annual Worldwide Developers Conference, where the company is expected to unveil new AI features embedded in iOS 19. The conference will be an opportunity for Apple to address several headwinds it has faced this year. "In a nutshell WWDC is a pivotal moment in Apple's future as the developers are the hearts and lungs of the Cupertino growth story with the Street being laser-focused on Apple today," Wedbush analyst Dan Ives wrote. The tech giant has trailed peers like Microsoft and Google in the AI race, and its stock has taken a beating this year as the worst-performing Magnificent Seven member, largely due to concerns about tariffs and iPhone production. Last month, Trump threatened a tariff of at least 25% on iPhones not made in the US. Investors will be looking for updates on Apple Intelligence as well, as the company's AI offering has been underwhelming to Wall Street. The US Treasury sells a lot of bonds, and usually the sale is unremarkable for markets. However, with deficit concerns running high as the GOP budget bill moves through Congress, a $22 billion auction of 30-year bonds on Thursday could move the market if demand appears weak. A weak sale of 20-year bonds last month rattled markets and sent yields surging, and all eyes are on this week's sale as a potential investor referendum on the sweeping tax and spending bill. Read the original article on Business Insider Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
HER2+ Gastric Cancer (including GEJ) Market to Increase at a Remarkable Growth Rate of 13% During the Study Period (2020-2034)
The overall HER2+ gastric cancer market is projected to grow, driven by increasing biomarker testing, better patient selection, and continued advancements in HER2-targeted ADCs, bispecific antibodies, and novel immune-based approaches. Additionally, the launch of therapies such as Zanidatamab (Jazz Pharmaceuticals), Rilvegostomig (AstraZeneca), Evorpacept (ALX Oncology), and others in the future is expected to bring a positive shift in the treatment landscape of HER2+ gastric cancer. LAS VEGAS, June 9, 2025 /PRNewswire/ -- DelveInsight's HER2+ Gastric Cancer (including GEJ) Market report includes a comprehensive understanding of current treatment practices, emerging HER2+ gastric cancer therapies, market share of individual therapies, and current and forecasted HER2+ gastric cancer market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Key Takeaways from the HER2+ Gastric Cancer Market Report As per DelveInsight's analysis, the total market size of HER2+ gastric cancer (including GEJ) in the 7MM is approximately USD 700 million in 2024 and is projected to increase during the forecast period (2025–2034). In 2024, among the current therapies for HER2+ gastric cancer, the largest revenue was generated by Trastuzumab ± Chemotherapy, i.e., USD 140 million in the United States. The total number of incident cases of HER2+ gastric cancer in the 7MM accounted for approximately. 45,000 in 2024. These cases are expected to increase by 2034. Leading HER2+ gastric cancer companies, such as AstraZeneca/Daiichi Sankyo, Merck, Jazz Pharmaceuticals, BeiGene, Zymeworks, Shanghai Henlius Biotech, AbClon, ALX Oncology, Artiva Biotherapeutics, GC Cell, KLUS Pharma, Shanghai Miracogen, Pfizer, Bayer, Enliven Therapeutics, Ambrx, NovoCodex, Mersana Therapeutics, GSK, SystImmune, and others, are developing novel HER2+ Gastric cancer therapies that can be available in the HER2+ gastric cancer market in the coming years. Daiichi Sankyo and AstraZeneca's ENHERTU (trastuzumab deruxtecan), is the only approved therapy for the treatment of advanced or metastatic HER2+ gastric cancer for 2L therapy. The drug received accelerated approval in January 2021. Along with ENHERTU (trastuzumab deruxtecan), KEYTRUDA (pembrolizumab), and HERCEPTIN (trastuzumab) are approved for HER2+ gastric cancer for 1L therapy. Daiichi Sankyo and AstraZeneca's ENHERTU is also expanding into the first-line treatment setting, which is expected to increase its patient share and, consequently, drive growth in the market size. Some of the key HER2+ gastric cancer emerging therapies in the pipeline include ZIIHERA (zanidatamab), Rilvegostomig, HLX22 (AC101), Evorpacept (ALX148), TUKYSA (tucatinib), BAY2927088, AB-201 (GCC2003, HER2 CAR-NK), A166 (Trastuzumab botidotin), MRG002, AIDIXI (disitamab vedotin), BAY2701439, ELVN-002, ARX788, XMT-2056, BL-M07D1, and others. Data presented during the recent ASCO 2025 meeting showed that ENHERTU extended overall survival for more than 3 months in patients with advanced HER2-positive gastric or GEJA following progression on first-line therapy, based on the Phase III DESTINY-Gastric04 trial. In February 2025, AstraZeneca anticipated a data readout from the Phase Ib/II (NCT04379596, DESTINY-Gastric03) trial, which was focused on treating metastatic or unresectable HER2+ gastric cancer, GEJ, and GEA, in 2026. In February 2025, AstraZeneca expected the first patient dosing of ENHERTU (NCT06731478, DESTINY-Gastric05) for HER2+ first-line locally advanced or metastatic gastric cancer or GEJ adenocarcinoma to begin in Q1 2025, with data anticipated to be available after 2026. In the January 2025 presentation, Jazz Pharmaceuticals anticipated the potential approval and launch of zanidatamab as a first-line treatment for GEA in 2026. Additionally, the company is also looking forward to expanding its market strategy for zanidatamab in 2026. In January 2025, ALX Oncology presented positive updated data from the ASPEN-06 Phase II clinical trial at the 2025 ASCO Gastrointestinal Cancers Symposium, demonstrating that the company's investigational CD47-blocker, evorpacept, produces a durable clinical response and exhibits a well-tolerated safety profile in patients with previously treated HER2+ advanced gastric cancer or GEJ cancer. Discover which therapies are expected to grab the HER2+ gastric cancer market share @ HER2+ Gastric Cancer Market Report HER2+ Gastric Cancer Overview Gastric cancer is the fifth most common type of cancer and the fourth leading cause of cancer-related deaths worldwide. HER2, also known as HER2/neu or ERBB2, is found in approximately 15–30% of gastric cancers, including those at the Gastroesophageal Junction (GEJ). It is located on chromosome 17q21 and is part of the EGFR family, which includes EGFR/HER1, HER3, and HER4. The ligand for the HER2 tyrosine kinase receptor remains unidentified. HER2 can form both homodimers and heterodimers with other EGFR family receptors, and overexpression of HER2 can result in ligand-independent activation. In gastric cancer, ERBB2 mutations are most commonly found in the CIN subtype, primarily consisting of missense mutations (74%), with smaller proportions of insertions (22%) and fusions (0.7%). HER2 expression is more frequently observed in the intestinal subtype (according to Lauren's classification), as well as in proximal gastric cancer, GEJ cancer, metastatic disease (particularly liver metastasis), and lymph node involvement. HER2+ Gastric Cancer Epidemiology Segmentation In the 7MM, in 2024, among all the HER2+ Gastric cancer indications, breast cancer accounted for the highest number of incident cases, while ovarian cancer occupied the bottom of the ladder. The HER2+ gastric cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Incident Cases of Gastric Cancer (including GEJ) Gender-Specific Cases of Gastric Cancer (including GEJ) Stage-Specific Cases of Gastric Cancer (including GEJ) Total Incident Cases of HER2+ Gastric Cancer (including GEJ) Total Incident Cases of Advanced HER2+ Gastric Cancer (including GEJ) HER2+ Gastric Cancer Treatment Market HER2, which is overexpressed or amplified in 6–36% of gastric cancer patients, represents a key target in the development of novel treatment strategies for metastatic gastric cancer. While surgical resection remains the primary treatment and can cure patients with early-stage cancer, the survival rates for those with advanced resectable gastric or gastroesophageal junction cancers remain low, despite the introduction of new treatments like perioperative chemotherapy or adjuvant chemoradiation. For patients diagnosed with early-stage disease, gastrectomy is the standard treatment. However, survival rates for those with advanced resectable cancers are still poor, even with the addition of new therapies such as perioperative chemotherapy or adjuvant chemoradiation. Treatment for HER2-positive gastric cancer depends on factors such as tumor size, location, and the patient's overall health. The humanized monoclonal antibody HERCEPTIN (trastuzumab) targets HER2, inhibiting the growth and survival of HER2-dependent tumors. Alongside HERCEPTIN, KEYTRUDA (Merck), one of the first therapies approved for gastric cancer, works by binding to the Programmed Cell Death-1 (PD-1) receptor, blocking its interaction with PD-L1 and PD-L2, and reversing PD-1 pathway-mediated immune suppression, including the antitumor immune response. Most recent approvals for targeted therapies, such as ENHERTU (Daiichi Sankyo) and AIDIXI (Remegen Biosciences), are used in second- and third-line treatments for gastric cancer. Learn more about the FDA-approved HER2+ gastric cancer therapies @ HER2+ Gastric Cancer Treatment Drugs Key Emerging HER2+ Gastric Cancer and Companies Various new therapies are in development with a focus on the mentioned limitations of the currently approved drugs. Some of the most prominent ones include Evorpacept (ALX Oncology), Zanidatamab (Jazz Pharmaceuticals), IAM1363 (Iambic Therapeutics), ELVN-002 (Enliven Therapeutics), ARX788 (Ambrx), Rilvegostomig (AstraZeneca), and others. These emerging drugs play a vital part in fulfilling the unmet need for the treatment approach of HER2+ gastric cancer. Although the space is quite active and various trials are underway to treat patients with HER2+ gastric cancer, continuous efforts are further needed to develop novel drugs that would be more effective and less toxic. ZIIHERA is a bispecific antibody targeting HER2, binding to two extracellular sites on the HER2 protein. In November 2024, the FDA granted accelerated approval for ZIIHERA for adult patients with previously treated, unresectable, or metastatic HER2+ (immunohistochemistry 3+) biliary tract cancer (BTC), identified through an FDA-approved test. Jazz Pharmaceuticals expects to release top-line data in the second quarter of 2025 from the Phase III HERIZON-GEA-01 trial (NCT05152147), which is assessing zanidatamab combined with chemotherapy, with or without tislelizumab, as a first-line treatment for HER2-positive metastatic gastric and esophageal adenocarcinoma (GEA). According to the presentation, Jazz Pharmaceuticals aims to potentially approve and launch zanidatamab as a first-line treatment for gastric cancer in 2026. The company is also planning to expand its market strategy for zanidatamab in 2026. HLX22 (AC101), a novel anti-HER2 monoclonal antibody developed by AbClon and further advanced by Henlius, is currently under investigation. In November 2024, Henlius Biotech announced that the first patient was dosed in the Phase III international multicenter clinical trial (HLX22-GC-301) for HLX22. In October 2024, Henlius received approval from Japan's PMDA for the Clinical Trial Notification (CTN) of a Phase III international multicenter study of HLX22, in combination with trastuzumab and chemotherapy, as a first-line treatment for HER2-positive advanced gastric cancer. The other therapies in the HER2+ gastric cancer pipeline include TUKYSA (tucatinib): Pfizer BAY2927088: Bayer AB-201 (GCC2003, HER2 CAR-NK): Artiva Biotherapeutics and GC Cell A166 (Trastuzumab botidotin): KLUS Pharma MRG002: Shanghai Miracogen AIDIXI (disitamab vedotin): Pfizer BAY2701439: Bayer XMT-2056: Mersana Therapeutics and GSK BL-M07D1: SystImmune and others The anticipated launch of these emerging therapies are poised to transform the HER2+ gastric cancer market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the HER2+ gastric cancer market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about HER2+ gastric cancer drug clinical trials, visit @ HER2+ Gastric Cancer Drugs HER2+ Gastric Cancer Market Dynamics The HER2+ gastric cancer market dynamics are expected to change in the coming years. HER2-targeted therapies, such as HERCEPTIN, ENHERTU, and anti-PD1 therapy KEYTRUDA, offer more precise treatment by improving efficacy and minimizing side effects compared to traditional chemotherapy. Daiichi Sankyo and AstraZeneca's ENHERTU is expanding into the first-line treatment setting, which is expected to increase its patient share and drive market growth. There is growing research interest in combining next-generation HER2 inhibitors or bispecific antibodies with Immune Checkpoint Inhibitors (ICIs), presenting significant opportunities to enhance treatment efficacy and improve patient survival. Additionally, the HER2+ gastric cancer market is projected to grow due to increased incidence rates, an aging population, and advancements in treatment methodologies, potentially leading to more investment in research and development. Furthermore, potential therapies are being investigated for the treatment of HER2+ gastric cancer, and it is safe to predict that the treatment space will significantly impact the HER2+ gastric cancer market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the HER2+ gastric cancer market in the 7MM. However, several factors may impede the growth of the HER2+ gastric cancer market. HER2+ gastric cancer is an aggressive form of the disease with a significantly high mortality rate, poor survival rates, and a poor prognosis due to factors such as low screening rates, high rates of refractory/relapsed tumors, and the advanced age of patients. The complexity of tumor biology, including intratumoral heterogeneity, poses challenges to effective treatment strategies and limits the efficacy of current therapies. Additionally, HER2+ gastric cancer is prone to developing resistance to targeted therapies, highlighting the need for the continuous development of next-generation agents, which further increases R&D costs. Moreover, HER2+ gastric cancer treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the HER2+ gastric cancer market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the HER2+ gastric cancer market growth. HER2+ Gastric Cancer Report Metrics Details Study Period 2020–2034 HER2+ Gastric Cancer Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] HER2+ Gastric Cancer Market CAGR 13 % HER2+ Gastric Cancer Market Size in 2024 USD 700 Million Key HER2+ Gastric Cancer Companies AstraZeneca/Daiichi SankyoJazz Pharmaceuticals, BeiGene, Zymeworks, Merck, Shanghai Henlius Biotech, AbClon, ALX Oncology, Artiva Biotherapeutics, GC Cell, KLUS Pharma, Shanghai Miracogen, Pfizer, Bayer, Enliven Therapeutics, Ambrx, NovoCodex, Mersana Therapeutics, GSK, SystImmune, and others Key HER2+ Gastric Cancer Therapies ENHERTU, KEYTRUDA, ZIIHERA (zanidatamab), Rilvegostomig, HLX22 (AC101), Evorpacept (ALX148), TUKYSA (tucatinib), BAY2927088, AB-201 (GCC2003, HER2 CAR-NK) A166 (Trastuzumab botidotin), MRG002, AIDIXI (disitamab vedotin), BAY2701439, ELVN-002, ARX788, XMT-2056, BL-M07D1, and others Scope of the HER2+ Gastric Cancer Market Report HER2+ Gastric Cancer Therapeutic Assessment: HER2+ Gastric Cancer current marketed and emerging therapies HER2+ Gastric Cancer Market Dynamics: Conjoint Analysis of Emerging HER2+ Gastric Cancer Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, HER2+ Gastric Cancer Market Access and Reimbursement Discover more about HER2+ gastric cancer drugs in development @ HER2+ Gastric Cancer Clinical Trials Table of Contents 1 Key Insights 2 Report Introduction 3 Executive Summary 4 Epidemiology and Market Methodology 5 HER2+ Gastric Cancer Market Overview at a Glance 5.1 Market Share (%) Distribution of HER2+ Gastric Cancer by Line of Therapies in 2020 in the 7MM 5.2 Market Share (%) Distribution of HER2+ Gastric Cancer by Line of Therapies in 2034 in the 7MM 5.3 Market Share (%) Distribution of HER2+ Gastric Cancer by Therapies in 2020 in the 7MM 5.4 Market Share (%) Distribution of HER2+ Gastric Cancer by Therapies in 2034 in the 7MM 6 Key Events 7 Disease Background and Overview 7.1 Introduction 7.2 Molecular Subtypes of Gastric Cancer 7.3 HER2+ Gastric Cancer 7.4 Causes and Risk Factors Related to Gastric Cancer 7.5 Clinical Manifestations Related to Gastric Cancer 7.6 Diagnosis Related to Gastric Cancer 7.7 Staging of Gastric Cancer 7.8 Current Treatment Practices: Gastric Cancer 7.8.1 Treatment for HER2+ Gastric Cancer 8 Guidelines and Recommendations for HER2+ Gastric Cancer 8.1 PAN-ASIAN ADAPTED (PAGA) ESMO CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS, TREATMENT, AND FOLLOW-UP OF PATIENTS WITH GASTRIC CANCER (2024) 8.2 NATIONAL COMPREHENSIVE CANCER NETWORK (NCCN) GUIDELINES FOR GASTRIC CANCER (2024) 8.3 NICE GUIDELINES FOR OESOPHAGO-GASTRIC CANCER (2023) 8.4 GASTRIC CANCER: ESMO CLINICAL PRACTICE GUIDELINE FOR DIAGNOSIS, TREATMENT AND FOLLOW-UP (2022) 8.5 JAPANESE GASTRIC CANCER TREATMENT GUIDELINES (2021) 9 Epidemiology and Patient Population 9.1 Key Findings 9.2 Assumptions and Rationale: 7MM 9.3 Total Incident Cases of Gastric Cancer (including GEJ) in the 7MM 9.4 United States 9.4.1 Total Incident Cases of Gastric Cancer (including GEJ) in the United States 9.4.2 Gender-specific Cases of Gastric Cancer (including GEJ) in the United States 9.4.3 Stage-specific Cases of Gastric Cancer (including GEJ) in the United States 9.4.4 Total Incident Cases of HER2+ Gastric Cancer (including GEJ) in the United States 9.4.5 Total Incident Cases of Advanced HER2+ Gastric Cancer (including GEJ) in the United States 9.5 EU4 and the UK 9.5.1 Total Incident Cases of Gastric Cancer (including GEJ) in EU4 and the UK 9.5.2 Gender-specific Cases of Gastric Cancer (including GEJ) in EU4 and the UK 9.5.3 Stage-specific Cases of Gastric Cancer (including GEJ) in EU4 and the UK 9.5.4 Total Incident Cases of HER2+ Gastric Cancer (including GEJ) in EU4 and the UK 9.5.5 Total Incident Cases of Advanced HER2+ Gastric Cancer in EU4 and the UK 9.6 Japan 9.6.1 Total Incident Cases of Gastric Cancer (including GEJ) in Japan 9.6.2 Gender-specific Cases of Gastric Cancer (including GEJ) in Japan 9.6.3 Stage-specific Cases of Gastric Cancer (including GEJ) in Japan 9.6.4 Total Incident Cases of HER2+ Gastric Cancer (including GEJ) in Japan 9.6.5 Total Incident Cases of Advanced HER2+ Gastric Cancer (including GEJ) in Japan 10 Patient Journey 11 Marketed Drug 11.1 Key Competitors 11.2 KEYTRUDA (pembrolizumab): Merck 11.2.1 Product Description 11.2.2 Regulatory Milestones 11.2.3 Other Development Activities 11.2.4 Clinical Development 11.2.5 Safety and Efficacy 11.3 ENHERTU (trastuzumab deruxtecan): Daiichi Sankyo and AstraZeneca 11.3.1 Product Description 11.3.2 Regulatory Milestones 11.3.3 Other Development Activities 11.3.4 Clinical Development 11.3.5 Safety and Efficacy 12 Emerging Therapies 12.1 Key Cross Competition 12.2 ZIIHERA (zanidatamab): Jazz Pharmaceuticals, BeiGene, and Zymeworks 12.2.1 Product Description 12.2.2 Other Developmental Activities 12.2.3 Clinical Development 12.2.4 Safety and Efficacy 12.3 Rilvegostomig: AstraZeneca 12.3.1 Product Description 12.3.2 Clinical Development 12.4 HLX22 (AC101): Shanghai Henlius Biotech and AbClon 12.4.1 Product Description 12.4.2 Other Development Activity 12.4.3 Clinical Development 12.4.4 Safety and Efficacy 12.5 Evorpacept (ALX148): ALX Oncology 12.5.1 Product Description 12.5.2 Other Developmental Activities 12.5.3 Clinical Development 12.5.4 Safety and Efficacy 12.6 TUKYSA (tucatinib): Pfizer 12.6.1 Product Description 12.6.2 Other Development Activity 12.6.3 Clinical Development 12.6.4 Safety and Efficacy 13 HER2+ Gastric Cancer (including GEJ): 7MM Analysis 13.1 Key Findings 13.2 Market Outlook 13.3 Conjoint Analysis 13.4 Key Market Forecast Assumptions 13.4.1 Cost Assumptions and Rebates 13.4.2 Pricing Trends 13.4.3 Analogue Assessment 13.4.4 Launch Year and Therapy Uptake 13.5 Total Market Size of HER2+ Gastric Cancer (including GEJ) in the 7MM 13.6 United States Market Size 13.6.1 Total Market Size of HER2+ Gastric Cancer (including GEJ) in the United States 13.6.2 Market Size of HER2+ Gastric Cancer (including GEJ) by Current and Emerging Therapies in the United States 13.7 EU4 and the UK Market Size 13.7.1 Total Market Size of HER2+ Gastric Cancer (including GEJ) in EU4 and the UK 13.7.2 Market Size of HER2+ Gastric Cancer (including GEJ) by Current and Emerging Therapies in EU4 and the UK 13.8 Japan Market Size 13.8.1 Total Market Size of HER2+ Gastric Cancer (including GEJ) in Japan 13.8.2 Market Size of HER2+ Gastric Cancer (including GEJ) by Current and Emerging Therapies in Japan 14 Unmet Needs 15 SWOT Analysis 16 KOL Views 17 Market Access and Reimbursement 17.1 United States 17.1.1 Centre for Medicare and Medicaid Services (CMS) 17.2 EU4 and the UK 17.2.1 Germany 17.2.2 France 17.2.3 Italy 17.2.4 Spain 17.2.5 United Kingdom 17.3 Japan 17.3.1 MHLW 17.4 Market Access and Reimbursement of HER2+ Gastric Cancer (including GEJ) 18 Appendix 18.1 Bibliography 18.2 Report Methodology 19 DelveInsight Capabilities 20 Disclaimer Related Reports HER2+ Gastric Cancer Pipeline HER2+ Gastric Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key HER2+ gastric cancer companies, including Jiangsu HengRui Medicine Co., Ltd., Pieris Pharmaceuticals, BioInvent International, Daiichi Sankyo, AstraZeneca, Shanghai JMT-Bio Inc., Acepodia Biotech, Inc., Klus Pharma Inc., Carisma Therapeutics Inc., Novartis Pharmaceuticals, Celularity Incorporated, Hoffmann-La Roche, DualityBio Inc., Shanghai Miracogen Inc., Bavarian Nordic, among others. HER2+ Gastric Cancer Epidemiology HER2+ Gastric Cancer Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the HER2+ gastric cancer epidemiology trends. Gastric Cancer Market Gastric Cancer Market Insight, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key gastric cancer companies, including Hanmi Pharmaceuticals, Merck, Minneamrita Therapeutics, Taiho Pharmaceuticals, Bayer, among others. Gastric Cancer Pipeline Gastric Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key gastric cancer companies, including EMD Serono, Sumitomo Pharma, LintonPharm Co., Ltd., Rapa Therapeutics LLC, Jiangsu HengRui Medicine Co., Ltd., Janssen Pharmaceutical K.K., Genentech, Exelixis, Bristol-Myers Squibb, Pieris Pharmaceuticals, Inc., Pfizer, Leap Therapeutics, CSPC ZhongQi Pharmaceutical, Ellipses Pharma, Amgen, Hanmi Pharmaceutical, Taiho Oncology, Inc., Shanghai Henlius Biotech, LianBio LLC, Chengdu Kanghong Biotech,Eisai Inc., AB Science, Maxinovel Pharmaceuticals, Shanghai Miracogen Inc., GlaxoSmithKline, Hoffmann-La Roche, Merck Sharp & Dohme, Hutchison Medipharma Limited, Genome & Company, Minneamrita Therapeutics LLC, Suzhou Suncadia Biopharmaceuticals Co., Ltd., MacroGenics, ALX Oncology Inc., Codiak BioSciences, Turning Point Therapeutics, Inc., TCRx Therapeutics, InxMed (Shanghai) Co., Ltd., Imugene Limited, SOTIO Biotech, CARsgen Therapeutics Co., Ltd., Zymeworks Inc., NextCure, Inc., Phanes Therapeutics, Pieris Pharmaceuticals, Inc., Athenex, Inc., Curis, Inc., Qurient Co., Ltd., Acepodia Biotech, Inc., Sichuan Baili Pharmaceutical Co., Ltd., Tarus Therapeutics, Inc., Lumicell, Inc., Legend Biotech,Cue Biopharma, TORL Biotherapeutics, LLC, OBI Pharma, Inc, Astellas Pharma, HiberCell, Inc., Celon Pharma SA, Linnaeus Therapeutics, Inc., Inspirna, Inc., Klus Pharma Inc., Genzada Pharmaceuticals, Shanghai PerHum Therapeutics, VM Oncology, LLC, Immunomic Therapeutics, Peptron, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact Us Shruti Thakur info@ +14699457679 Logo: View original content: SOURCE DelveInsight Business Research, LLP
Yahoo
2 hours ago
- Yahoo
CEA Industries Enters Canadian Vape Market with Completion of Fat Panda Acquisition
Closes Acquisition of Leading Vape Operator with 33 Locations and Over 50% Market Share in Central Canada Adds High-Margin, CAD $38.5 Million Revenue Platform to Accelerate Growth and Drive Shareholder Value Conference Call Scheduled for June 11, 2025 at 4:30pm ET to Review the Supporting Investor Presentation on the CEA Industries Website Louisville, Colorado, June 09, 2025 (GLOBE NEWSWIRE) -- CEA Industries Inc. (NASDAQ: CEAD, CEADW) ('CEA Industries' or the 'Company'), today announced the completion of its acquisition of Fat Panda Ltd. ('Fat Panda'), Central Canada's largest independent vape retailer and vertically integrated manufacturer. The acquisition accelerates CEA's strategic diversification while establishing a scalable platform in one of the fastest-growing sectors of the regulated nicotine market. Founded in 2013, Fat Panda operates 33 high-traffic retail locations across Manitoba, Ontario, and Saskatchewan, supported by a national e-commerce platform. The company's vertically integrated model includes ISO-certified manufacturing facilities for its e-liquid production and direct supplier relationships, enabling product consistency, streamlined sourcing, and improved cost structure. With over 50% regional market share and a loyal customer base, Fat Panda generated approximately CAD $38.5 million (USD $28.5 million) in revenue with 39% gross margins and CAD $8.0 million (USD $5.9 million) (before ownership distributions) in adjusted EBITDA in the fiscal year ended April 30, 2024, based on preliminary unaudited results. 'This acquisition marks a significant milestone for CEA as we expand into a dynamic, high-growth regulated vertical benefiting from strong consumer demand,' said Tony McDonald, Chairman and CEO of CEA Industries. 'Fat Panda brings an established brand, experienced leadership, and a highly profitable operating model that can be rapidly scaled with our capital and strategic support. Importantly, this acquisition exemplifies our commitment to identifying accretive opportunities that can unlock meaningful long-term value for our shareholders.' 'Joining CEA Industries provides the financial strength and operational support to accelerate our vision,' said Jordan Vedoya, Co-Founder and President of Fat Panda. 'We are excited to deepen our footprint, elevate our e-commerce presence, and continue delivering value through Fat Panda's customer-centric approach across Canada's regulated vape industry.' Fat Panda will operate under its existing brand led by the current management team to ensure a seamless transition with uninterrupted operations. Mr. Vedoya will also lead integration efforts and spearhead expansion across both retail and digital channels. Strategic Benefits of the Transaction Leads Central Canada's Regulated Vape Market – Fat Panda operates 33 corporate-owned stores across three provinces with over 50% regional market share, establishing immediate category leadership. Expands Scalable Omnichannel Platform – Combines a national e-commerce footprint with high-traffic retail locations, driving over CAD $2 million in annual online sales. Drives Margin Accretion Through Vertical Integration – In-house manufacturing and direct supplier relationships support 39% gross margins and CAD $8.0 million in adjusted EBITDA in fiscal year 2024. Establishes Durable Competitive Moat – Proprietary product formulations, a robust trademark portfolio, and regulatory alignment under the Tobacco and Vaping Products Act (TVPA) differentiate Fat Panda in the dynamic regulatory landscape. Enables Platform Growth Through Expansion and M&A – With CEA Industries capital and strategic support, Fat Panda is positioned to open new locations, acquire complementary retailers, and scale profitably across Canada. Transaction Terms The CAD $18.0 million (USD $12.6 million) purchase price comprises approximately CAD $12.1 million in cash, 39,000 shares of CEAD common stock with an agreed value of CAD $700,000, and seller notes totaling CAD $2.56 million. A portion of the purchase price was funded by a short-term loan from a United States based lender in the amount of USD $4.0 million, which is due in six months. In addition, CAD $2.6 million has been placed in escrow to support post-closing adjustments, indemnity obligations, and employee-related matters. Conference Call and Investor Presentation CEA Industries will host a conference call to discuss the acquisition and strategic implications for the Company on Wednesday, June 11, 2025 at 4:30pm ET. A live webcast and accompanying investor presentation will be available on the Investor Relations section of the Company's website at To access the call, please use the following information: Dial-in: 1-973-528-0008 Access Code: 891969 Webcast URL: A replay of the webcast will be available shortly after the event and archived online. About CEA Industries Inc. CEA Industries Inc. (NASDAQ: CEAD) is a growth-oriented company focused on building category-leading businesses in regulated consumer markets. With a focus on the high-growth, Canadian nicotine vape industry, one of the fastest-expanding segments of the global nicotine market, CEA Industries targets scalable operators with strong regulatory alignment, defensible market share, and high-margin business models. The Company provides capital, operational expertise, and strategic resources to accelerate retail expansion, strengthen e-commerce infrastructure, and drive long-term value creation in performance-driven sectors. For more information, visit Forward Looking Statements This press release may contain statements of a forward-looking nature relating to future events. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect our current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this press release, including the factors set forth in 'Risk Factors' set forth in our annual and quarterly reports filed with the Securities and Exchange Commission ('SEC'), and subsequent filings with the SEC. Please refer to our SEC filings for a more detailed discussion of the risks and uncertainties associated with our business, including but not limited to the risks and uncertainties associated with our business prospects and the prospects of our existing and prospective customers; the inherent uncertainty of product development; regulatory, legislative and judicial developments, especially those related to changes in, and the enforcement of, cannabis laws; increasing competitive pressures in our industry; and relationships with our customers and suppliers. Except as required by the federal securities laws, we undertake no obligation to revise or update any forward-looking statements, whether as a result of new information, future events or otherwise. The reference to CEA's website has been provided as a convenience, and the information contained on such website is not incorporated by reference into this press release. Non-GAAP Financial Measures To supplement our financial results on U.S. generally accepted accounting principles ('GAAP') basis, we use non-GAAP measures including net bookings and backlog, as well as other significant non-cash expenses such as stock-based compensation and depreciation expenses. We believe these non-GAAP measures are helpful in understanding our past performance and are intended to aid in evaluating our potential future results. The presentation of these non-GAAP measures should be considered in addition to our GAAP results and are not intended to be considered in isolation or as a substitute for financial information prepared or presented in accordance with GAAP. We believe these non-GAAP financial measures reflect an additional way to view aspects of our operations that, when viewed with our GAAP results, provide a more complete understanding of factors and trends affecting our business. Investor Contact: Sean Mansouri, CFA or Aaron D'SouzaElevate IRinfo@ (720) 330-2829
